Valuation check: VRCA's profit margin is -47.97%, below the Healthcare sector average of 15.58%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Verrica Pharmaceuticals (VRCA) currently reports a profit margin of -47.97% as of March 2026. That compares with -930.09% in the prior-year period — up 94.8% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Verrica Pharmaceuticals's profit margin history and peer comparisons.
Verrica Pharmaceuticals's profit margin increased from -930.09% to -47.97% — a 94.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Verrica Pharmaceuticals's profit margin of -47.97% is lower than the Healthcare sector average of 15.58%. That is roughly 407.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Verrica Pharmaceuticals's current -47.97% should be judged against Healthcare norms (sector average: 15.58%) and against VRCA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -47.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Verrica Pharmaceuticals, and consider following VRCA for alerts when major investors trade the stock.